LncRNA AK054921 and AK128652 are potential serum biomarkers and predictors of patient survival with alcoholic cirrhosis

Zhihong Yang, Ruth A Ross, Shi Zhao, Wanzhu Tu, Suthat Liangpunsakul, Li Wang – 2 August 2017 – Alcoholic liver disease (ALD) is one of the leading causes of chronic liver disease. Recent studies have demonstrated the roles of long noncoding RNAs (lncRNAs) in the pathogenesis of several disease processes. However, the roles of lncRNAs in patients with ALD remain unexplored.

Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: Facilitating development approaches for an emerging epidemic

Claudia Filozof, Shein‐Chung Chow, Lara Dimick‐Santos, Yeh‐Fong Chen, Richard N. Williams, Barry J. Goldstein, Arun Sanyal – 1 August 2017 – Due to the increasing prevalence of nonalcoholic steatohepatitis (NASH) and its associated health burden, there is a high need to develop therapeutic strategies for patients with this disease. Unfortunately, its long and asymptomatic natural history, the uncertainties about disease progression, the fact that most patients are undiagnosed, and the requirement for sequential liver biopsies create substantial challenges for clinical development.

Remodeling the model for end‐stage liver disease for predicting mortality risk in critically ill patients with cirrhosis and acute kidney injury

Xiao‐Dong Zhou, Qin‐Fen Chen, Dan‐Qin Sun, Chen‐Fei Zheng, Dong‐Jie Liang, Jian Zhou, Song‐Jie Wang, Wen‐Yue Liu, Sven Poucke, Xiao‐Dong Wang, Ke‐Qing Shi, Wei‐Jian Huang, Ming‐Hua Zheng – 1 August 2017 – Serum creatinine measurement demonstrates a poor specificity and sensitivity for the early diagnosis of acute kidney injury (AKI) in patients with cirrhosis. The existing model for end‐stage liver disease (MELD) score reveals multiple pitfalls in critically ill patients with cirrhosis and acute kidney injury (CAKI).

Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: Facilitating development approaches for an emerging epidemic

Claudia Filozof, Shein‐Chung Chow, Lara Dimick‐Santos, Yeh‐Fong Chen, Richard N. Williams, Barry J. Goldstein, Arun Sanyal – 1 August 2017 – Due to the increasing prevalence of nonalcoholic steatohepatitis (NASH) and its associated health burden, there is a high need to develop therapeutic strategies for patients with this disease. Unfortunately, its long and asymptomatic natural history, the uncertainties about disease progression, the fact that most patients are undiagnosed, and the requirement for sequential liver biopsies create substantial challenges for clinical development.

Hepatitis B cure: From discovery to regulatory approval

Anna S. Lok, Fabien Zoulim, Geoffrey Dusheiko, Marc G. Ghany – 1 August 2017 – The majority of persons currently treated for chronic hepatitis B require long‐term or lifelong therapy. New inhibitors of hepatitis B virus entry, replication, assembly, or secretion and immune modulatory therapies are in development. The introduction of these novel compounds for chronic hepatitis B necessitates a standardized appraisal of the efficacy and safety of these treatments and definitions of new or additional endpoints to inform clinical trials.

The selective peroxisome proliferator–activated receptor‐delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice

Fahrettin Haczeyni, Hans Wang, Vanessa Barn, Auvro R. Mridha, Matthew M. Yeh, W. Geoffrey Haigh, George N. Ioannou, Yun‐Jung Choi, Charles A. McWherter, Narcissus C.‐H. Teoh, Geoffrey C. Farrell – 31 July 2017 – Lipotoxicity associated with insulin resistance is central to nonalcoholic steatohepatitis (NASH) pathogenesis. To date, only weight loss fully reverses NASH pathology, but mixed peroxisome proliferator–activated receptor‐alpha/delta (PPAR‐α/δ) agonists show some efficacy. Seladelpar (MBX‐8025), a selective PPAR‐δ agonist, improves atherogenic dyslipidemia.

Subscribe to